Advanced Medical Optics Highlights Key Educational Courses at the American Society of Cataract and Refractive Surgery (ASCRS) An
13 April 2005 - 7:00PM
PR Newswire (US)
Advanced Medical Optics Highlights Key Educational Courses at the
American Society of Cataract and Refractive Surgery (ASCRS) Annual
Symposium AMO Also to Launch New Multifocal IOL and Delivery System
SANTA ANA, Calif., April 13 /PRNewswire-FirstCall/ -- Advanced
Medical Optics, Inc. (AMO) (NYSE:AVO), a global leader in
ophthalmic surgical devices and eye care products, today announced
several educational courses and presentations at the American
Society of Cataract and Refractive Surgery (ASCRS) annual symposium
April 16 - 19, 2005, in Washington, DC. The courses highlight AMO's
commitment to continuing education and technology. (Logo:
http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO) There are a
total of 37 scheduled doctor presentations and panel discussions
covering AMO's cataract and refractive technologies including the
ReZoom(TM), Tecnis(R) and Verisyse(TM) IOLs, Amadeus(TM) II
microkeratome and StabilEyes(TM) capsular tension ring, among
others. Some of the scheduled educational courses include: "An
Update on Multifocal Intraocular Lens Use in Refractive Cataract
Surgery" Randall Olson, M.D. will instruct a course that will
discuss considerations for use of multifocal lenses in the evolving
field of cataract/refractive surgery. Topics include patient
selection, biometry, limbal-relaxing incisions, and multifocal IOL
advancements. "Bimanual Micro-Phaco Cataract Surgery" Roger
Steinert, M.D. will instruct a course that will review the basics
and introduce latest innovations in bimanual
micro-phacoemulsification. Topics include transition to sleeveless
bimanual micro-phaco; machine settings and instrumentation;
complications and management; and clinical pearls. "Breakthroughs
in Improving Functional Vision after Cataract Surgery" Mark Packer,
M.D. will instruct a course to discuss innovations in
measuring/improving functional vision in elderly
post-phacoemulsification patients, safety benefits, optic design,
spherical aberration, and Wavefront analysis. In addition to these
and other educational courses, AMO will host a series of booth
presentations on its refractive, cataract and glaucoma surgical
technologies. For a complete schedule of AMO's educational courses
and booth presentations, please contact AMO or visit the AMO booth
during the academy meeting. AMO will be located in booth #943 at
the Washington Convention Center. AMO will also introduce two new
innovative products at the ASCRS symposium, including the
ReZoom(TM) IOL, a new design and next generation acrylic
three-piece multifocal IOL that was recently approved by the U.S.
Food and Drug Administration (FDA), and the Emerald XL Unfolder(TM)
implantation system. The ReZoom(TM) IOL with Balanced View
Optics(TM) technology distributes light over five optical zones for
enhanced restoration of visual function, providing distance,
intermediate and near vision for reduced spectacle dependence.
AMO's Emerald XL Unfolder(TM) system is used to implant the
Sensar(R) acrylic IOL with OptiEdge(TM) design. The Emerald XL
Unfolder(TM) implantation system offers increased control and
easier rotation because of its smaller threads and larger wheel.
Physicians can still insert a three- piece 6-mm optic acrylic IOL
through an unenlarged phaco incision as small as 2.8 mm. Along with
the ReZoom(TM) IOL and Emerald XL Unfolder(TM) system, AMO will
spotlight its core surgical brands in booth #943 at the ASCRS
symposium, including the Sovereign(R) phaco system with
WhiteStar(TM) technology, Verisyse(TM) and Tecnis(R) IOLs,
Amadeus(TM) II microkeratome, Baerveldt(R) glaucoma implant, and
Healon(R) and Vitax(R) ophthalmic viscosurgical devices. The
ReZoom(TM) IOL is indicated for the visual correction of aphakia in
adult patients in whom a cataractous lens has been removed and who
may benefit from useful near vision without reading glasses and
increased spectacle independence across a range of distances. These
devices are intended to be placed in the capsular bag. Multifocal
subjects should exercise caution when driving at night or in poor
visibility conditions. For a complete listing of precautions,
warnings and adverse events, refer to the package insert. Rx only.
About Advanced Medical Optics (AMO) AMO is a global leader in the
development, manufacturing and marketing of ophthalmic surgical and
eye care products. The company focuses on developing a broad suite
of innovative technologies and devices to address a wide range of
eye disorders. Products in the ophthalmic surgical line include
intraocular lenses, phacoemulsification systems, viscoelastics,
microkeratomes and related products used in cataract and refractive
surgery. AMO owns or has the rights to such ophthalmic surgical
product brands as ReZoom(TM), Phacoflex(R), Clariflex(R), Array(R),
Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses,
Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification
systems with WhiteStar(TM) technology, Amadeus(TM) and Amadeus(TM)
II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the
Baerveldt(R) glaucoma shunt. Products in the contact lens care line
include disinfecting solutions, daily cleaners, enzymatic cleaners
and lens rewetting drops. Among the contact lens care product
brands the company possesses are COMPLETE(R) Moisture PLUS(TM),
COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step,
Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and
blink(TM) branded products. Amadeus is a licensed product of, and a
trademark of, SIS, Ltd. OptiEdge(TM) is a registered trademark of
Ocular Sciences. AMO is based in Santa Ana, California, and employs
approximately 3,000 worldwide. The company has operations in about
20 countries and markets products in approximately 60 countries.
For more information, visit the company's Web site at
http://www.amo-inc.com/. Forward-Looking Statements Statements in
this press release regarding new product benefits, and any other
statements that refer to AMO's estimated or anticipated future
results are forward-looking statements. All forward-looking
statements in this press release reflect AMO's current analysis of
existing trends and information and represent AMO's judgment only
as of the date of this press release. Actual results may differ
from current expectations based on a number of factors affecting
AMO's businesses, including but not limited to unexpected changes
in competitive, regulatory and market conditions, AMO's ability to
obtain adequate product supply and product successful collaborative
efforts, unexpected litigation or intellectual property issues, and
the uncertainties associated with market acceptance of new
products. Therefore, the reader is cautioned not to rely on these
forward-looking statements. AMO disclaims any intent or obligation
to update these forward-looking statements. Additional information
concerning these and other risk factors may be found in previous
financial press releases issued by AMO. AMO's public periodic
filings with the Securities and Exchange Commission, including the
discussion under the heading "Certain Factors and Trends Affecting
AMO and its Businesses" in AMO's 2004 Form 10-K filed in March 2005
include information concerning these and other risk factors. Copies
of press releases and additional information about AMO are
available at http://www.amo-inc.com/, or you can contact the AMO
Investor Relations Department by calling 714-247-8348. Advanced
Medical Optics, Inc. Investors: Sheree Aronson (714) 247-8290
Media: Steve Chesterman (714) 247-8711
http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO
http://photoarchive.ap.org/ DATASOURCE: Advanced Medical Optics,
Inc. CONTACT: Investors, Sheree Aronson, +1-714-247-8290, ; or
Media, Steve Chesterman, +1-714-247-8711, , both for of Advanced
Medical Optics, Inc. Web site: http://www.amo-inc.com/
Copyright
Advanced medical Optics (NYSE:AVO)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Advanced medical Optics (NYSE:AVO)
Historical Stock Chart
Von Sep 2023 bis Sep 2024